Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

AMT-162

Gene therapy (AAV vector) · Gene silencing: superoxide dismutase 1 (SOD1) · developed by UniQure Biopharma B.V.

Phase 1/2 Most advanced trial
QURE Developer
1 Registered trials

What is AMT-162?

AMT-162 is a nonreplicating, self-complementary recombinant adeno-associated virus vector based on serotype rh10 that carries cDNA encoding an artificial microRNA targeting SOD1. It is being studied in amyotrophic lateral sclerosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Gene therapy (AAV vector)
Targets
superoxide dismutase 1 (SOD1)
Mechanism
Gene silencing: superoxide dismutase 1 (SOD1)
Therapy area
Neurology
Developer
UniQure Biopharma B.V. (QURE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06100276 Phase 1/2 Amyotrophic Lateral Sclerosis Active not recruiting QURE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Amyotrophic Lateral Sclerosis

Other drugs acting on SOD1

More from UniQure Biopharma B.V.

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the QURE page.

Follow QURE, the company behind AMT-162

See QURE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

QURE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.